Key Developments: Biomerieux SA (BIOX.PA)

BIOX.PA on Paris Stock Exchange

103.75EUR
22 May 2015
Change (% chg)

€4.08 (+4.09%)
Prev Close
€99.67
Open
€100.00
Day's High
€104.00
Day's Low
€100.00
Volume
33,478
Avg. Vol
40,446
52-wk High
€104.00
52-wk Low
€76.32

Search Stocks

Latest Key Developments (Source: Significant Developments)

Biomerieux unit Biofire submits de novo classification request to FDA
Tuesday, 14 Apr 2015 01:00am EDT 

Biomerieux SA:Biofire submits de novo application to FDA for FilmArray meningitis/encephalitis panel.Submission comes after successful completion of a clinical study.  Full Article

Biomerieux SA to propose FY 2014 dividend and issues FY 2015 financial guidance
Wednesday, 11 Mar 2015 02:10am EDT 

Biomerieux SA:Says higher contributive operating income before non-recurring items is expected in 2015.Says priority action plans to sustainably strengthen operating performance.Says to have set an organic growth objective of between 4.5 pct and 6.5 pct for 2015.To propose dividend of 1 euro per share, unchanged from dividend paid in 2014.  Full Article

Biomerieux unit BioFire receives FDA clearance for the FilmArray 2.0 system
Thursday, 26 Feb 2015 01:00am EST 

Biomerieux SA:BioFire receives FDA clearance for the FilmArray 2.0 system.System is expected to be commercially available by end of March 2015.  Full Article

Biomerieux and Astute Medical to develop and market Nephrocheck test
Thursday, 22 Jan 2015 01:00am EST 

Biomerieux SA:Biomerieux and Astute Medical sign a global agreement to develop and market Nephrocheck test for Vidas, an assay to assess the risk of developing acute kidney injury.Test detects the presence of two biomarkers: TIMP-2 (Tissue Inhibitor Metalloproteinases-2) and IGFBP-7 (Insulin-like Growth Factor-Binding Protein-7).  Full Article

Biomerieux signs strategic alliance with Copan
Friday, 9 Jan 2015 01:00am EST 

Biomerieux SA:Strategic alliance signed between Biomerieux and Copan to automate clinical microbiology laboratories and enhance their operational efficiency.Copan has granted distribution rights for its automated platforms to Biomerieux.Agreement with Copan to speed up deployment of company FMLA - lab efficiency vision for automation and enhanced operational efficiency of clinical microbiology lab.  Full Article

Biomerieux agrees with Illumina to launch NGS epidemiology solution for service labs
Tuesday, 18 Nov 2014 01:00am EST 

Biomerieux SA:Signs exclusive agreement with Illumina to launch next-generation sequencing (NGS) epidemiology solution for service labs.Companies are to jointly develop applications for microbiology sequencing technologies within four-year renewable period.  Full Article

Biomerieux gets FDA fast-track authorization of Ebola test
Monday, 27 Oct 2014 02:00am EDT 

Biomerieux SA:Says its Biofire Defense unit receives fast-track authorization of FilmArray Ebola test.Says authorization received from U.S. Food and Drug Administration (FDA).  Full Article

Biomerieux announces acquisition of Advencis
Wednesday, 22 Oct 2014 01:00am EDT 

Biomerieux SA:Says it acquired all outstanding shares in Alsace-based Advencis (France).Advencis has developed an incubator system for rapidly detecting microbial contaminants in water used in manufacturing, particularly by pharmaceutical companies.Acquisition price, including an initial payment and contingent consideration linked to the success of the next development stages, could reach up to a total of 10 million euros.  Full Article

Biomerieux confirms FY 2014 financial targets
Wednesday, 3 Sep 2014 01:00am EDT 

Biomerieux SA:Confirms FY 2014 objective of 3-5 pct sales growth.Maintains its FY 2014 target to achieve contributive operating income before non-recurring items of 220-245 million euros.  Full Article

Biomerieux SA's Virtuo receives CE-mark
Wednesday, 23 Jul 2014 01:00am EDT 

Biomerieux SA:Announces that Virtuo, part of BacT/ALERT product range, has been CE-marked.Virtuo is automated blood culture microbial detection system.  Full Article

BRIEF-Biomerieux Q1 revenue rises to 447.9 million euros

* Q1 revenue 447.9 million euros ($479.79 million) versus 370.8 million euros a year ago

Search Stocks